Vivian Ng

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng et al. · Gastric Cancer · 2014 · 588 citations · Full text

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Sara A. Hurvitz, Luc Dirix, Judit Kocsis et al. · Journal of Clinical Oncology · 2013 · 389 citations

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

Valérie Cosson, Vivian Ng, Michaela Lehle et al. · Cancer Chemotherapy and Pharmacology · 2014 · 102 citations

Oncology, Esophageal Cancer, Gastrointestinal Oncology +12

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Patrick Schöffski, Sara Cresta, Ingrid A. Mayer et al. · Breast Cancer Research · 2018 · 87 citations · Full text

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

Ian E. Krop, Stephen Johnston, Ingrid A. Mayer et al. · Cancer Research · 2015 · 60 citations

Breast Oncology, Pi3k Inhibitor Pictilisib, Gynecology +20